MD4080B1 - Utilizare a molsidominei pentru prevenirea sau incetinirea dezvoltarii aterosclerozei - Google Patents

Utilizare a molsidominei pentru prevenirea sau incetinirea dezvoltarii aterosclerozei Download PDF

Info

Publication number
MD4080B1
MD4080B1 MDA20060241A MD20060241A MD4080B1 MD 4080 B1 MD4080 B1 MD 4080B1 MD A20060241 A MDA20060241 A MD A20060241A MD 20060241 A MD20060241 A MD 20060241A MD 4080 B1 MD4080 B1 MD 4080B1
Authority
MD
Moldova
Prior art keywords
molsidomine
atherosclerosis
slow
development
prevent
Prior art date
Application number
MDA20060241A
Other languages
English (en)
Other versions
MD4080C1 (ro
Inventor
Jozsef-Michel Geczy
Original Assignee
Therabel Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therabel Pharmaceuticals Limited filed Critical Therabel Pharmaceuticals Limited
Publication of MD4080B1 publication Critical patent/MD4080B1/ro
Publication of MD4080C1 publication Critical patent/MD4080C1/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Inventia se refera la o noua aplicare terapeutica a unei compozitii ce contine molsidomina sau una dintre sarurile ei farmaceutic acceptabile, in special sub forma de compozitie solida orala, cu eliberare prelungita a molsidominei si o eficienta timp de 24 ore, pentru prevenirea sau reducerea progresarii aterosclerozei.
MDA20060241A 2004-04-05 2005-04-01 Utilizare a molsidominei pentru prevenirea sau încetinirea dezvoltării aterosclerozei MD4080C1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0403534A FR2868314B1 (fr) 2004-04-05 2004-04-05 Nouvelle utilisation therapeutique de la molsidomine et de ses sels pharmaceutiquement acceptables
PCT/EP2005/003531 WO2005107761A1 (fr) 2004-04-05 2005-04-01 Composition orale de la molsidomine a liberation prolongee pour le traitement de l’atherosclerose

Publications (2)

Publication Number Publication Date
MD4080B1 true MD4080B1 (ro) 2010-12-31
MD4080C1 MD4080C1 (ro) 2011-07-31

Family

ID=34944920

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20060241A MD4080C1 (ro) 2004-04-05 2005-04-01 Utilizare a molsidominei pentru prevenirea sau încetinirea dezvoltării aterosclerozei

Country Status (28)

Country Link
US (1) US7754715B2 (ro)
EP (1) EP1732565B8 (ro)
JP (1) JP5117847B2 (ro)
KR (1) KR101162385B1 (ro)
CN (1) CN1938032B (ro)
AU (1) AU2005239799B2 (ro)
BE (1) BE1016580A3 (ro)
BR (1) BRPI0509642A (ro)
CA (1) CA2562287C (ro)
CY (1) CY1117614T1 (ro)
DK (1) DK1732565T3 (ro)
ES (1) ES2567576T3 (ro)
FR (1) FR2868314B1 (ro)
HR (1) HRP20160479T1 (ro)
HU (1) HUE029199T2 (ro)
IL (1) IL178440A0 (ro)
IT (1) ITTO20050220A1 (ro)
MA (1) MA28518B1 (ro)
MD (1) MD4080C1 (ro)
NO (1) NO336913B1 (ro)
NZ (1) NZ550341A (ro)
PL (1) PL1732565T3 (ro)
RS (1) RS54791B1 (ro)
RU (1) RU2388475C2 (ro)
SI (1) SI1732565T1 (ro)
UA (1) UA88461C2 (ro)
WO (1) WO2005107761A1 (ro)
ZA (1) ZA200608219B (ro)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2617494T3 (es) * 2012-05-31 2017-06-19 G. Pohl-Boskamp Gmbh & Co. Kg Inducción de arteriogénesis con un donador de óxido nítrico tal como nitroglicerina

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385937A (en) * 1991-04-10 1995-01-31 Brigham & Women's Hospital Nitrosation of homocysteine as a method for treating homocysteinemia
FR2805462B1 (fr) * 2000-02-24 2003-08-15 Therabel Res Nouvelle forme galenique orale a liberation prolongee de la molsidomine
US6472390B1 (en) * 2001-11-13 2002-10-29 Duke University Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure
KR100464876B1 (ko) * 2001-11-15 2005-01-06 학교법인 인제학원 동충하초의 코르디세핀을 함유하는 항혈전제 조성물
WO2010062256A1 (en) * 2008-11-27 2010-06-03 Nanyang Polytechnic Process and system for automatic identification of the larvae of aedes albopictus and aedes aegypti

Also Published As

Publication number Publication date
KR101162385B1 (ko) 2012-07-06
CA2562287A1 (fr) 2005-11-17
CN1938032A (zh) 2007-03-28
ES2567576T3 (es) 2016-04-25
CA2562287C (fr) 2013-05-14
HRP20160479T1 (hr) 2016-06-03
CY1117614T1 (el) 2017-04-26
DK1732565T3 (en) 2016-05-09
US7754715B2 (en) 2010-07-13
EP1732565B8 (fr) 2016-05-11
ZA200608219B (en) 2008-02-27
FR2868314B1 (fr) 2008-10-24
IL178440A0 (en) 2007-02-11
RS54791B1 (sr) 2016-10-31
HK1092736A1 (zh) 2007-02-16
RU2006134695A (ru) 2008-05-20
JP2007531781A (ja) 2007-11-08
US20070212413A1 (en) 2007-09-13
MD4080C1 (ro) 2011-07-31
AU2005239799A1 (en) 2005-11-17
EP1732565A1 (fr) 2006-12-20
MA28518B1 (fr) 2007-04-03
WO2005107761A1 (fr) 2005-11-17
BRPI0509642A (pt) 2007-09-18
CN1938032B (zh) 2010-06-09
FR2868314A1 (fr) 2005-10-07
NZ550341A (en) 2009-11-27
NO20064510L (no) 2006-10-31
UA88461C2 (ru) 2009-10-26
ITTO20050220A1 (it) 2005-10-06
AU2005239799B2 (en) 2010-12-23
KR20070015534A (ko) 2007-02-05
EP1732565B1 (fr) 2016-03-09
RU2388475C2 (ru) 2010-05-10
HUE029199T2 (en) 2017-03-28
BE1016580A3 (fr) 2007-02-06
NO336913B1 (no) 2015-11-23
PL1732565T3 (pl) 2016-08-31
JP5117847B2 (ja) 2013-01-16
SI1732565T1 (sl) 2016-06-30

Similar Documents

Publication Publication Date Title
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
SE0100172D0 (sv) New inhibitors against galectins
ATE545413T1 (de) Antagonisten des opioidrezeptors
ME02688B (me) Hinazolinoni kao inhibitori humane fosfatidilinozitol 3 - kinaze delta
MY147786A (en) Substituted morpholine and thiomorpholine derivatives
EA200970161A1 (ru) Производные 1-(-d-гликопиранозил)-3-(4-циклопропилфенилметил)-4-галогеноиндола и их применение в качестве ингибиторов sglt
TW200635582A (en) Medicaments for the treatment or prevention of fibrotic diseases
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
CY1108738T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για την αγωγη του πονου
ATE440603T1 (de) 8-hydroxychinolinderivate
IS2533B (is) (S)-2-N-própýlamínó-5-hýdroxýetralín sem D3-gerandefni
BRPI0412999A (pt) 2-aminotetralina substituìda para tratamento de depressão
IS2517B (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
BR0211972A (pt) Composição oftálmica
WO2004014869A3 (en) 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
NO20075022L (no) (7-(2-(4-(3-trifluormetylfenyl)-1,2,3,6-tetrahydropyrid-1-yl)etyl) isokinolinbesylatsalt, fremstilling og terapeutiske anvendelser derav
TNSN06138A1 (fr) Inhibitors of the mutant form of kit
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
ATE475640T1 (de) Antagonisten des opioidrezeptors
ATE447575T1 (de) Selektive spirocyclische glucocorticoid-rezeptor- modulatoren
EA200701181A1 (ru) Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten

Legal Events

Date Code Title Description
FG4A Patent for invention issued
MK4A Patent for invention expired